Development of vaccines against tuberculosis (Q37844882)

24 August 2017

1 reference

title

Development of vaccines against tuberculosis (English)

1 reference

24 August 2017

0 references

Anil K Tyagi

1

1 reference

PubMed ID

21334259

24 August 2017

Prachi Nangpal

series ordinal

2

1 reference

PubMed ID

21334259

24 August 2017

Vijaya Satchidanandam

series ordinal

3

1 reference

24 August 2017

18 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

91

1 reference

24 August 2017

5

1 reference

24 August 2017

469-478

1 reference

Host innate immune response to Mycobacterium tuberculosis

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Innate immunity to Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Macrophage--Mycobacterium tuberculosis interactions: role of complement receptor 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

The many faces of macrophage activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Regulatory T cells and transcription factors: gatekeepers in allergic inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Mycobacterium bovis BCG vaccination induces memory CD4+ T cells characterized by effector biomarker expression and anti-mycobacterial activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Modeling the impact of global tuberculosis control strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Characterization of novel immunodominant antigens of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Antigenic definition of plasma membrane proteins of Bacillus Calmette-Guérin: predominant activation of human T cells by low-molecular-mass integral proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Serological distinction of integral plasma membrane proteins as a class of mycobacterial antigens and their relevance for human T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

A major T-cell-inducing cytosolic 23 kDa protein antigen of the vaccine candidate Mycobacterium habana is superoxide dismutase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

The antigens of Mycobacterium bovis, strain BCG, studied by crossed immunoelectrophoresis: a reference system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

The antigens of Mycobacterium tuberculosis, H37Rv, studied by crossed immunoelectrophoresis. Comparison with a reference system for Mycobacterium bovis, BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Superoxide dismutase from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

ESAT-6 subunit vaccination against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

The regulatory elements of the Mycobacterium tuberculosis gene Rv3881c function efficiently in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

A mycobacterial virulence gene cluster extending RD1 is required for cytolysis, bacterial spreading and ESAT-6 secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

The co-operonic PE25/PPE41 protein complex of Mycobacterium tuberculosis elicits increased humoral and cell mediated immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Human immune recognition-based multicomponent subunit vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Adjuvant modulation of T-cell reactivity to 30-kDa secretory protein of Mycobacterium tuberculosis H37Rv and its protective efficacy against experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Potent role of vaccines prepared from macrophages infected with live bacteria in protection against Mycobacterium tuberculosis and Salmonella typhimurium infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

New use of BCG for recombinant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Cloning and assessment of mycobacterial promoters by using a plasmid shuttle vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

A study of mycobacterial transcriptional apparatus: identification of novel features in promoter elements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Mycobacterial transcriptional signals: requirements for recognition by RNA polymerase and optimal transcriptional activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Construction of shuttle vectors for genetic manipulation and molecular analysis of mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Identification of immunodominant antigens during infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Evidence for a partial redundancy of the fibronectin-binding proteins for the transfer of mycoloyl residues onto the cell wall arabinogalactan termini of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Mycobacterium tuberculosis H37Rv comparative gene-expression analysis in synthetic medium and human macrophage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette-Guérin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Immunogenicity of candidate chimeric DNA vaccine against tuberculosis and leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Advances in tuberculosis vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Boosting vaccine for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol Mycobacterium tuberculosis infection in guinea pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

The use of the name Mycobacterium w for the leprosy immunotherapeutic bacillus creates confusion with M. tuberculosis-W (Beijing strain): a suggestion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

An immunotherapeutic vaccine for multibacillary leprosy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Differential immunogenicity of novel Mycobacterium tuberculosis antigens derived from live and dead bacilli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.01.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TUBE.2011.01.003

1 reference

24 August 2017

1 reference

PubMed ID

21334259